Mirae Asset Global Investments Co., Ltd. Sorrento Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$22.5 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.74 - $1.83 $108,614 - $268,600	146,776 Added 9.72%	1,657,557 $1.48 Million
Q3 2022 Nov 10, 2022	BUY	$1.51 - $2.88 $265,322 - $506,044	175,710 Added 13.16%	1,510,781 $2.37 Million
Q2 2022 Jul 26, 2022	BUY	$1.24 - $2.33 $532,237 - $1 Million	429,224 Added 47.38%	1,335,071 $2.68 Million
Q1 2022 May 10, 2022	SELL	$2.0 - $4.9 $298,792 - $732,040	-149,396 Reduced 14.16%	905,847 $2.11 Million
Q4 2021 Feb 08, 2022	BUY	$4.65 - $7.23 $1.25 Million - $1.94 Million	268,257 Added 34.09%	1,055,243 $4.91 Million
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $1.14 Million - $1.7 Million	154,327 Added 24.39%	786,986 $6.01 Million
Q2 2021 Aug 11, 2021	BUY	$6.35 - $10.0 $800,633 - $1.26 Million	126,084 Added 24.89%	632,659 $6.13 Million
Q1 2021 May 13, 2021	BUY	$7.03 - $16.51 $1.63 Million - $3.83 Million	231,840 Added 84.39%	506,575 $4.19 Million
Q4 2020 Feb 10, 2021	BUY	$5.76 - $11.95 $831,409 - $1.72 Million	144,342 Added 110.7%	274,735 $1.88 Million
Q3 2020 Nov 12, 2020	BUY	$6.17 - $18.82 $257,184 - $784,474	41,683 Added 46.99%	130,393 $1.45 Million
Q2 2020 Aug 11, 2020	BUY	$1.73 - $6.76 $78,867 - $308,174	45,588 Added 105.72%	88,710 $557,000
Q1 2020 May 12, 2020	BUY	$1.57 - $4.76 $7,556 - $22,909	4,813 Added 12.56%	43,122 $79,000
Q4 2019 Feb 12, 2020	SELL	$1.45 - $4.17 $16,648 - $47,879	-11,482 Reduced 23.06%	38,309 $129,000
Q3 2019 Nov 12, 2019	BUY	$2.05 - $2.69 $75,442 - $98,994	36,801 Added 283.3%	49,791 $107,000
Q2 2019 Aug 13, 2019	BUY	$2.67 - $4.38 $34,683 - $56,896	12,990 New	12,990 $35,000

Others Institutions Holding SRNE

# of Institutions

Shares Held

5.47M

Call Options Held

Put Options Held

View Full List

About Sorrento Therapeutics, Inc.

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

More about SRNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account